Neos Therapeutics, Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020	Q1 FY2020 As of Mar 31, 2020	Q4 FY2019 As of Dec 31, 2019	Q3 FY2019 As of Sep 30, 2019	Q2 FY2019 As of Jun 30, 2019	Q1 FY2019 As of Mar 31, 2019	Q4 FY2018 As of Dec 31, 2018	Q3 FY2018 As of Sep 30, 2018	Q2 FY2018 As of Jun 30, 2018	Q1 FY2018 As of Mar 31, 2018	Q4 FY2017 As of Dec 31, 2017	Q3 FY2017 As of Sep 30, 2017	Q2 FY2017 As of Jun 30, 2017	Q1 FY2017 As of Mar 31, 2017	Q4 FY2016 As of Dec 31, 2016	Q3 FY2016 As of Sep 30, 2016	Q2 FY2016 As of Jun 30, 2016	Q1 FY2016 As of Mar 31, 2016	Q4 FY2015 As of Dec 31, 2015
ASSETS
Current Assets:
Cash and cash equivalents
Short-term investments
Accounts receivable, net of allowances for chargebacks and cash discounts of $1,899 and $4,848 at September 30, 2020 and December 31, 2019, respectively
Inventories, net
Deferred contract sales organization fees
Prepaid expenses and other current assets
Total current assets

Property and equipment, net
Operating lease right-of-use assets
Intangible assets, net
Other assets
Total assets
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
Accounts payable
Contract sales organization payable
Accrued expenses
Deferred revenue
Current portion of operating lease liabilities
Short-term line of credit
Current portion of long-term debt
Total current liabilities

Long-Term Liabilities:
Long-term debt
Earnout liability
Net gain on sale leaseback
Operating lease liabilities
Derivative liability
Deferred rent
Other long-term liabilities
Total long-term liabilities

Stockholders' Deficit:
Common stock, $0.001 par value, 100,000,000 shares authorized at September 30, 2020 and December 31, 2019; 49,788,895 and 49,755,094 shares issued and outstanding, respectively, at June 30, 2020; 49,766,472 and 49,732,671 shares issued and outstanding, respectively, at December 31, 2019
Treasury stock, at cost, 18,906 shares at March 31, 2017 and December 31, 2016
Treasury stock, at cost, 33,801 shares at September 30, 2020 and December 31, 2019
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income
Total stockholders' deficit

Total liabilities and stockholders' deficit

Comments